Liquid biopsy firm Inivata Ltd. has completed a $52.6m Series B funding round to support commercialization of its blood-test for non-small cell lung cancer (NSCLC) diagnosis. The funding is backed by Woodford Patient Capital Trust, IP Group, Cambridge Innovation Capital, Johnson & Johnson Innovation and RT Ventures.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?